KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Payables (2016 - 2025)

Historic Payables for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $1.2 billion.

  • BeOne Medicines' Payables rose 28921.87% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 28921.87%. This contributed to the annual value of $1.3 billion for FY2024, which is 29875.66% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Payables is $1.2 billion, which was up 28921.87% from $360.8 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Payables ranged from a high of $1.3 billion in Q4 2024 and a low of $146.9 million during Q1 2021
  • Over the past 5 years, BeOne Medicines' median Payables value was $294.8 million (recorded in 2022), while the average stood at $376.0 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 5371.91% in 2021, then surged by 29875.66% in 2024.
  • BeOne Medicines' Payables (Quarter) stood at $262.4 million in 2021, then grew by 12.34% to $294.8 million in 2022, then grew by 6.9% to $315.1 million in 2023, then skyrocketed by 298.76% to $1.3 billion in 2024, then fell by 4.74% to $1.2 billion in 2025.
  • Its Payables was $1.2 billion in Q3 2025, compared to $360.8 million in Q2 2025 and $364.5 million in Q1 2025.